Compass Therapeutics (CMPX) Operating Expenses (2018 - 2026)

Compass Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $20.3 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 12.99% year-over-year to $20.3 million; the TTM figure through Mar 2026 stood at $75.2 million (up 19.94% YoY), while the FY2025 annual figure was $72.8 million, up 26.73% from the prior year.
• Operating Expenses came in at $20.3 million for Q1 2026 at Compass Therapeutics, up from $18.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $21.1 million in Q2 2025 to a low of $7.2 million in Q1 2022.
• A 5-year average of $14.3 million and a median of $13.3 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 115.2% in 2022 and declined 5.33% in 2023, its largest moves.
• Compass Therapeutics' Operating Expenses stood at $12.9 million in 2022, then grew by 19.44% to $15.4 million in 2023, then advanced by 7.67% to $16.6 million in 2024, then rose by 8.54% to $18.0 million in 2025, then climbed by 12.83% to $20.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $20.3 million, $18.0 million, and $15.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison